IFS Advisors’s Flexion Therapeutics, Inc. FLXN Stock Holding History

IFS Advisors’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-400	Closed	-$4K	–	175
2020 Q4	$4K	Buy	+400	New	+$4.65K	﹤0.01%	136

Other funds holding FLXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

IFS Advisors's FLXN Position: Q1 2021 in Review

IFS Advisors sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2021, closing a stake of 400 shares — an estimated $4K sold.

IFS Advisors first reported a position in FLXN in Q4 2020 and held it in 1 quarter. The position peaked at $4K in Q4 2020. 145 funds tracked by Wall St. Rank hold FLXN as of Q1 2021.

IFS Advisors reported no remaining Flexion Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
IFS Advisors sold 400 Flexion Therapeutics, Inc. shares in Q1 2021, an estimated $4K.
IFS Advisors first reported a position in Flexion Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
IFS Advisors's Flexion Therapeutics, Inc. position peaked at $4K in Q4 2020.
145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2021.

Based on IFS Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.